ABUS
Arbutus Biopharma Corporation
ABUS's fundamentals are strong: revenue grew more than tenfold and its operating margin went from −320% to 81%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ABUS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Unavailable |
ABUS's revenue, profitability and cash flow are currently healthy. There isn't enough data to rate its balance sheet.
ABUS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 3.6x | $4.03 | — |
| Cheap | 5.2x | $5.83 | +45% |
| Fair | 5.5x | $6.20 | +54% |
| Expensive | 6.3x | $7.07 | +75% |
Historical ranges are pointers, not guarantees.
ABUS's PE is 3.6x, but its earnings don't support one, so it isn't a reliable read right now.
ABUS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect ABUS's losses to shrink, with revenue growing.
ABUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $1.13 | +$1.36 |
| Q2 2026 | $0.79 | +$1.08 |
| Q1 2026 | $0.83 | +$1.24 |
| Q4 2025 | -$0.17 | +$0.21 |
| Q3 2025 | -$0.23 | +$0.20 |
| Q2 2025 | -$0.29 | +$0.16 |
| Q1 2025 | -$0.41 | +$0.03 |
| Q4 2024 | -$0.38 | +$0.06 |
ABUS has returned to profit: it earned $1.13 per share over the past year, after losing money the year before.
ABUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $299K | -43% |
| Q2 2026 | $1M | -91% |
| Q1 2026 | $179.1M | +10055% |
| Q4 2025 | $1.1M | -33% |
| Q3 2025 | $529K | -60% |
| Q2 2025 | $10.7M | +522% |
| Q1 2025 | $1.8M | +15% |
| Q4 2024 | $1.6M | -27% |
ABUS's revenue is growing: $299,000 last quarter, down 43% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3510% | -1873 points |
| Q2 2026 | -588% | -602 points |
| Q1 2026 | 94% | +1551 points |
| Q4 2025 | -503% | +382 points |
| Q3 2025 | -1637% | -36 points |
| Q2 2025 | 14% | +1264 points |
| Q1 2025 | -1457% | -193 points |
| Q4 2024 | -885% | +82 points |
ABUS's operating margin was −3510% last quarter, down 1873 points from the same quarter a year ago, near the bottom of its range since 2019.
ABUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $239.8M | +$245.6M |
| Q2 2026 | -$6M | +$9.7M |
| Q1 2026 | -$8.1M | +$5.3M |
| Q4 2025 | -$4.7M | +$5.7M |
| Q3 2025 | -$5.8M | +$14.9M |
| Q2 2025 | -$15.7M | -$1.2M |
| Q1 2025 | -$13.4M | +$6M |
| Q4 2024 | -$10.4M | +$6.9M |
ABUS's free cash flow has turned positive after six years mostly in the red: $221M over the past year.
ABUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +2.2M shares |
| 1 year | +4.1% | +7.8M shares |
| 3 years | +19% | +32.1M shares |
| 5 years | +106% | +103M shares |
| Available history | +190% | +131M shares |
ABUS has 200M diluted shares, up 4.1% from a year ago.
ABUS Net Leverage
ABUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.0 | Neutral |
| Stochastic | 12.4 | Oversold |
ABUS's weekly RSI is 42 (neutral) and its Stochastic is 12 (oversold).
ABUS PE vs Healthcare Sector
| Metric | ABUS | Sector median | Relative |
|---|---|---|---|
| PE | 3.6x | 26x | 86% below |
| PE % | 0 | 29 | 29 pts below |
ABUS is trading at 3.6x earnings, a 86% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ABUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.23 | 4.7% below |
| 20 week MA | $4.58 | 12% below |
| 50 week MA | $4.45 | 9.4% below |
| 100 week MA | $4.03 | 0% above |
| 200 week MA | $3.43 | 17% above |
ABUS has fallen below most of its moving averages, though it's still 17% above its 200-week average.
ABUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.49 | $3.87 | +55% |
| 2021 | $3.87 | $4.16 | +7.5% |
| 2022 | $4.16 | $2.39 | -43% |
| 2023 | $2.39 | $2.50 | +4.6% |
| 2024 | $2.50 | $3.21 | +28% |
| 2025 | $3.21 | $4.78 | +49% |
| 2026 YTD | $4.78 | $4.03 | -16% |
ABUS has finished higher in five of the last six years. It's down 16% so far in 2026.